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As health care budgets are under pressure, evaluation of
cost-effectiveness is of increasing importance to provide
arguments to insurance companies to pay for diagnostic
procedures or for specific treatments. Methodology for
cost-effectiveness analyses has been evolving over the last
years but is still complex and based on various assump-
tions. In their study, Van Nooten et al. evaluated the cost-
effectiveness of lipid-lowering therapy in patients with
coronary heart disease or type 2 diabetes [1]. The authors
conclude that the combination of ezetimibe and simvastatin
is cost-effective in primary prevention of vascular events in
patients not achieving the advocated low-density lipopro-
tein cholesterol (LDL-C) goal of 2.5 mmol/l on statin
treatment alone. The methodology used in the paper to
estimate and calculate costs is common practice in the
economic evaluation of health care costs. On the effectivity
side of the paper, the authors assume that LDL-C reduction
with statin monotherapy compared with combination
therapy with ezetimibe and statin is equally effective in
reducing the risk of cardiovascular events. However, there
is no evidence from randomised clinical trials, with clinical
events as endpoints, showing that the results from statin
monotherapy trials can be extrapolated to risk reduction by
LDL-C reduction as a result of combination therapy.
Nevertheless, it is not unrealistic to accept that vascular
risk reduction largely depends on LDL-C reduction
irrespective of the pharmacological modality leading to
that LDL-C reduction. Clinical endpoint studies using non-
statin interventions such as bile acid sequestrants or with
ileum bypass [2] show LDL-C reductions associated with a
reduction in vascular events. It is most likely that vascular
event reduction is indeed caused by LDL-C reduction. The
results of large randomised endpoint trials, evaluating the
effect of ezetimibe on vascular endpoints, are expected in
2012. As Van Nooten et al. correctly point out, in clinical
trials in patients with diabetes, the combination of statin/
ezetimibe was associated with lower carotid intima-media
thickness compared with statin alone. It should be noted
that in familial hypercholesterolaemia patients, the addition
of ezetimibe on maximal statin dose did not affect carotid
intima-media thickness.
During the last few years, the costs of statin therapy have
dropped dramatically due to expiring patent protection. The
costs of 1-year statin treatment are about €50–60 , including
pharmacy costs. Even in the light of these dramatic low
costs, the combination treatment of statin/ezetimibe is cost-
effective due to a sizeable additional LDL-C reduction on
top of statin treatment, compared with small incremental
reduction of LDL-C when the statin dose is increased. In
the original EASEGO study [3], 67% of patients in the
statin/ezetimibe combination arm reached the LDL-C goal
of 2.5 mmol/l compared with 26% in the doubling statin
dose group. If combination treatment ultimately proves to
reduce hard clinical endpoints, the combination of
inhibiting cholesterol synthesis and inhibiting cholesterol
absorption may become standard, cost-effective, practice
in patients not reaching LDL-C goals on statin therapy
alone.
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